Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.62 |
| ▸ | PI4KA | P42356 | 4/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | SCN4A | P35499 | 3/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101125 | 0.86 | PIK3CD (0.58) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL10183352 | 0.83 | RAB9A (0.50) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL20101061 | 0.79 | MEN1 (0.50) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL25307122 | 0.77 | PI4KA (1.00) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL31114551 | 0.77 | PI4KA (1.00) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL25493442 | 0.75 | PI4KA (0.67) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL19270394 | 0.73 | PIK3CD (0.59) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL3711581 | 0.73 | ALDH1A1 (0.48) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL29924638 | 0.73 | ALDH1A1 (0.48) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA | |
| SCHEMBL21186294 | 0.71 | RAB9A (0.59) | PIK3CDPI4KAPIK3CGPI4KBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3419981-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | Indiana University Research & Technology Corporation (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-08-23 | — | — | US | disclosed |
| WO-2018081612-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ACTAVALON, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017147312-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147312-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | PIK3CD 3371/4885PI4KA 3490/4885PIK3CG 2794/4885 |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | SMN1; SMN2, MUSK, MYOF | PIK3CD 3371/4885PI4KA 3490/4885PIK3CG 2794/4885 |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | PIK3CD 3371/4885PI4KA 3490/4885PIK3CG 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.